NMRD vs. INVO, QNRX, DYNT, BJDX, TNON, AEMD, IONM, STSS, AFIB, and UTRS
Should you be buying Nemaura Medical stock or one of its competitors? The main competitors of Nemaura Medical include INVO Bioscience (INVO), Quoin Pharmaceuticals (QNRX), Dynatronics (DYNT), Bluejay Diagnostics (BJDX), Tenon Medical (TNON), Aethlon Medical (AEMD), Assure (IONM), Sharps Technology (STSS), Acutus Medical (AFIB), and Minerva Surgical (UTRS). These companies are all part of the "surgical & medical instruments" industry.
INVO Bioscience (NASDAQ:INVO) and Nemaura Medical (NASDAQ:NMRD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
INVO Bioscience has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than INVO Bioscience, indicating that it is currently the more affordable of the two stocks.
In the previous week, INVO Bioscience had 9 more articles in the media than Nemaura Medical. MarketBeat recorded 9 mentions for INVO Bioscience and 0 mentions for Nemaura Medical. Nemaura Medical's average media sentiment score of 0.35 beat INVO Bioscience's score of 0.00 indicating that INVO Bioscience is being referred to more favorably in the media.
12.0% of INVO Bioscience shares are owned by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are owned by institutional investors. 3.5% of INVO Bioscience shares are owned by insiders. Comparatively, 41.6% of Nemaura Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
INVO Bioscience has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500.
Nemaura Medical has a net margin of 0.00% compared to Nemaura Medical's net margin of -459.42%.
Nemaura Medical has a consensus target price of $2.50, indicating a potential upside of 3,372.22%. Given INVO Bioscience's higher probable upside, analysts clearly believe Nemaura Medical is more favorable than INVO Bioscience.
INVO Bioscience received 3 more outperform votes than Nemaura Medical when rated by MarketBeat users. However, 57.14% of users gave Nemaura Medical an outperform vote while only 46.67% of users gave INVO Bioscience an outperform vote.
Summary
INVO Bioscience beats Nemaura Medical on 9 of the 16 factors compared between the two stocks.
Get Nemaura Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMRD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NMRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nemaura Medical Competitors List
Related Companies and Tools
